Amalgamation of Astra Healthcare with a Promoter-Controlled Transferee
Astra Healthcare Limited, an unlisted public company with 4,200 shareholders, has applied to the NCLT for sanction of a scheme of amalgamation with Astra Lifesciences Private Limited, in which the Managing Director and his family hold 68%. The appointed date is 1 April 2024. Under the exchange ratio of one Astra Lifesciences share for every three Astra Healthcare shares, the promoter family's holding in the merged entity will rise from 41% to 63%. The scheme contains a clause that a ₹4.5 crore income-tax demand on the transferor "shall not be enforceable against the transferee". The statutory auditor of Astra Healthcare is also the valuer of the shares. The NCLT has directed meetings of members and creditors. At the members' meeting, 88% in value voted in favour and the 8% institutional block voted against; the creditors' meeting approved with 76% in value. The tax department has filed objections.
1. Can the NCLT sanction the scheme despite the dissent of the 8% institutional block, and what should the Tribunal scrutinise?
Read the worked answer
Threshold is satisfied. Section 230(6) requires the scheme to be approved by members representing three-fourths in value of those present and voting. The 88% favourable vote clears that threshold, so the 8% block cannot veto the scheme; on sanction the scheme binds the company, its members, creditors and the liquidator.
But a threshold is not a blank cheque. The NCLT must independently be satisfied that the scheme is fair, reasonable and not contrary to public policy, and that the statutory procedure has been followed. The following need scrutiny here:
- Valuation independence. The statutory auditor of the transferor is also the valuer. Section 230(4) requires the notice of the meeting to disclose all material facts, including the valuation report, and the report must be capable of withstanding scrutiny. An interested or non-independent valuer is a classic ground for the NCLT to direct a fresh valuation by an independent registered valuer, or to refuse sanction.
- Related-party character. The transferee is promoter-controlled, the ratio shifts the promoter stake from 41% to 63%, and the fairness of the 1:3 ratio to the minority must be demonstrated, not assumed.
- Notice to authorities. The Section 230(5) notices must have gone to the Registrar, the income-tax authorities and any other sectoral regulator within three days of the Tribunal's direction, with a 30-day window for representations.
- Accounting treatment. Section 232(6) requires the scheme to state a specified accounting treatment, which must comply with the applicable standards.
The Tribunal may sanction with modifications, or refuse.
2. Is the clause disclaiming the ₹4.5 crore tax demand effective against the Income Tax Department? How should the objection be handled?
Read the worked answer
A scheme cannot extinguish a statutory liability. Section 232 gives the Tribunal power to sanction a compromise or amalgamation, and the order binds the company, its members, creditors and the liquidator. That is a private-law power. It does not authorise the company and the Tribunal to annul a demand payable under the Income-tax Act: a tax liability is a statutory obligation, not a contractual claim that the parties can allocate away.
Effect of Section 232(2). On sanction, the undertaking, property, assets, rights, liabilities and duties of the transferor stand transferred to and vest in the transferee. The ₹4.5 crore demand therefore travels to the transferee. A clause saying it "shall not be enforceable" is ineffective against the Revenue; at best it is an inter se arrangement that may give the transferee a claim against the transferor's former promoters, but the Department can proceed against the transferee.
Procedure. The Department was entitled to notice under Section 230(5) and to make its representation within 30 days. Its objection cannot be brushed aside: the NCLT should hear it and may sanction the scheme subject to a direction that the transferee discharges the demand, or in an appropriate case refuse sanction if the scheme is a device to defeat public revenue. The company should obtain a tax clearance or provide for the demand in the scheme itself rather than relying on a disclaimer.
Related point. Because the 88% approval falls short of the 90% needed for the fast-track route under Section 233, and the transferee is not a small company or wholly owned subsidiary, the Section 230–232 route is the only one available.
3. Does the increase in the promoter family's holding to 63% trigger any additional regulatory approval in this case? Explain your reasoning.
Read the worked answer
Identify the regulator test first. Whether an open offer is triggered depends on the status of the company whose shares are being acquired. The SEBI Takeover Code applies to acquisitions in listed companies. Astra Healthcare Limited is expressly an unlisted public company, so the change in shareholding from 41% to 63% consequent on the amalgamation does not attract an open offer obligation, and SEBI is not a regulator to whom notice under Section 230(5) must be sent on that ground.
But the enquiry does not end there. Two further checks are necessary:
- If the merged entity is to be listed, or if the scheme is a step towards listing, the position changes and SEBI's and the stock exchange's observations become relevant.
- The acquisition is by persons in control of the transferor, so the fairness of the exchange ratio and the valuation is a live issue before the NCLT; the increase in control is a factor going to whether the scheme is oppressive to the minority, even though it is not a takeover-code issue.
Other consents. The scheme must still comply with the conditions in the Memorandum and Articles, any shareholder agreement, and any sectoral licence held for the healthcare business, and the Section 230(5) notice must go to the Registrar and the income-tax authorities. Stamp duty on the order of amalgamation must also be paid on the transfer of assets.
Conclusion. No Takeover Code open offer arises solely because the company is unlisted, but the control shift must be disclosed and justified before the NCLT.